Recurrent Head and Neck Carcinoma
Information
- Disease name
- Recurrent Head and Neck Carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00954226 | Active, not recruiting | Phase 1 | Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer | August 5, 2009 | March 31, 2025 |
| NCT01638533 | Active, not recruiting | Phase 1 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | June 12, 2012 | March 5, 2025 |
| NCT02465060 | Active, not recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | August 17, 2015 | December 31, 2025 |
| NCT02474368 | Active, not recruiting | Phase 1 | Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck | November 2015 | June 2024 |
| NCT03049618 | Active, not recruiting | Phase 2 | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | March 10, 2017 | March 10, 2026 |
| NCT03892720 | Active, not recruiting | N/A | Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer | March 27, 2019 | April 1, 2026 |
| NCT04514484 | Active, not recruiting | Phase 1 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | November 22, 2021 | November 2, 2025 |
| NCT02467738 | Completed | Early Phase 1 | Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer | March 17, 2015 | May 28, 2020 |
| NCT01696955 | Completed | Phase 2 | Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery | August 20, 2012 | May 5, 2017 |
| NCT01727076 | Completed | Phase 1 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | February 15, 2013 | June 30, 2016 |
| NCT01846091 | Completed | Phase 1 | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer | April 9, 2013 | November 26, 2019 |
| NCT02318771 | Completed | Phase 1 | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | February 5, 2015 | March 25, 2021 |
| NCT02646319 | Completed | Early Phase 1 | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | January 2016 | April 24, 2018 |
| NCT03727061 | Recruiting | Phase 1 | Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer | July 10, 2019 | December 10, 2024 |
| NCT03164460 | Recruiting | Phase 2 | Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in Treating Patients With Recurrent Head and Neck Cancer | May 22, 2017 | May 31, 2025 |
| NCT05980000 | Recruiting | Phase 2 | Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma | October 27, 2023 | April 30, 2031 |
| NCT02706691 | Terminated | Phase 2 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | June 1, 2018 | February 11, 2019 |